Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 7/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.37 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CFTR | P13569 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20265568 | 0.88 | MALT1 (0.47) | MALT1ADORA2AADORA2BTRPM4NPC1 | |
| SCHEMBL23928432 | 0.81 | CFTR (0.44) | MALT1ADORA2AADORA2BADORA3CYP2C19 | |
| SCHEMBL20283653 | 0.80 | MALT1 (0.45) | MALT1TRPM4CFTR | |
| SCHEMBL29971684 | 0.80 | MALT1 (0.45) | MALT1TRPM4CFTR | |
| SCHEMBL20265550 | 0.73 | PIN1 (0.35) | MALT1ADORA2AADORA2BNPC1SMN1; SMN2 | |
| SCHEMBL24869524 | 0.72 | MALT1 (0.51) | MALT1NPC1 | |
| SCHEMBL20265085 | 0.70 | PLAU (0.37) | MALT1ADORA2AADORA2B | |
| SCHEMBL20278394 | 0.70 | HPGDS (0.33) | MALT1ADORA2AADORA2BLRRK2 | |
| SCHEMBL23928410 | 0.69 | MALT1 (0.58) | MALT1 | |
| SCHEMBL24869563 | 0.67 | MALT1 (0.32) | MALT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11230545-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-01-25 | — | — | US | disclosed |
| US-20210332045-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11230545-B2 | Heterocyclic compound | MALT1, SQSTM1, PPM1D | MALT1 1/4885ADORA2A 4808/4885ADORA2B 4885/4885 |
| US-20210332045-A1 | HETEROCYCLIC COMPOUND | MALT1, SQSTM1, PPM1D | MALT1 1/4885ADORA2A 4808/4885ADORA2B 4885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.